Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 23Myelodysplastic Syndromes 6Myeloproliferative Disorders 5Glioma 5Cholangiocarcinoma 5Leukemia 3Wilms Tumor 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Neoplasm Metastasis 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Hematologic Neoplasms 2Ependymoma 2Chondrosarcoma 2Biliary Tract Neoplasms 2Xanthogranuloma, Juvenile 1Pancreatic Ductal Adenocarcinoma 1Neoplasms, Unknown Primary 1Neoplasm, Residual 1Lymphoma, Follicular 1IDH1-Mutated Malignancies 1

Interventions

ivosidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × IDH1-Mutated Malignancies × ivosidenib × Clear all
NCT07006688 2026-05-12

A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

Servier

Phase 1 Recruiting
30 enrolled

IDH1-Mutated Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡